latest health care news

02.03.20

NHS England approves funding for drug to help rare conditions

To celebrate World Rare Diseases Day, NHS England has confirmed it has struck a deal to fund a potentially life-changing treatment for people with rare conditions causing repeated bouts of fever, joint pains and swelling.

The NHS has said the treatment has been approved in an effort to help a small group of people who “suffer in silence” with periodic fever syndromes (PFS), a group of rare genetic conditions where the person’s immune system overreacts, resulting in frequent inflammation ‘flares’ involving chest or join pains, headaches, mouth ulcers and skin rash.

Canakinumab, the drug a deal has been struck to fund, modifies the immune system, turning off the inflammation process, significantly reducing the number of ‘flares’ children and adults experience.

The deal with a global pharmaceutical firm has been agreed after negotiations led by the NHS, as part of a major programme to ramp up access to innovative treatments, while freeing up funding for frontline patient care through smarter procurement.

By agreeing this deal, the NHS now has access to a more effective, convenient drug with fewer side effects to existing treatments.

It follows contracts agreed in recent months to introduce new drugs for restoring sight and cystic fibrosis.

READ MORE: NHS will ‘unleash full innovation potential’ with new drugs and test beds

Sir Simon Stevens, chief executive of NHS England, said: “Some illnesses affect a small number in a big way, which is why the NHS is increasingly bringing innovative, specialised and targeted treatments to people who need them.

“This latest new treatment has the potential to significantly improve the lives of children who bear the burden of bouts of crippling pain which blights lives and puts strain on families.

“It’s the latest in a line of major deals NHS England has successfully negotiated, which show that when drug companies play ball with the NHS, taxpayers get a fair deal and patients get cutting-edge treatments.”

There are an estimated 168 patients in England with these diseases, both children and adults, and around 80% of these would be prescribed canakinumab.

Comments

There are no comments. Why not be the first?

Add your comment

 

national health executive tv

more videos >

featured articles

View all News

last word

Haseeb Ahmad: ‘We all have a role to play in getting innovations quicker’

Haseeb Ahmad: ‘We all have a role to play in getting innovations quicker’

Haseeb Ahmad, president of the Association of the British Pharmaceutical Industry (ABPI), sits down with National Health Executive as part of our Last Word Q&A series. Would you talk us throu more > more last word articles >

health service focus

View all News

comment

NHS England dementia director prescribes rugby for mental health and dementia patients

23/09/2019NHS England dementia director prescribes rugby for mental health and dementia patients

Reason to celebrate as NHS says watching rugby can be good for your mental ... more >
Peter Kyle MP: It’s time to say thank you this Public Service Day

21/06/2019Peter Kyle MP: It’s time to say thank you this Public Service Day

Taking time to say thank you is one of the hidden pillars of a society. Bei... more >

interviews

Organ Donation Week: Having the conversation

11/09/2020Organ Donation Week: Having the conversation

As part of Organ Donation Week, NHE’s Matt Roberts spoke with our Man... more >

the scalpel's daily blog

NICE’s support for rebuilding capacity in non-Covid health services

18/09/2020NICE’s support for rebuilding capacity in non-Covid health services

Paul Chrisp, Director of the Centre for Guidelines, NICE When the Covid-19 pandemic hit the UK’s shores earlier this year, the NHS responded quickly, diverting and ... more >
read more blog posts from 'the scalpel' >